Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1342935.RA8h_LShjGvH3a5uCYXStBIvuvBpVGIljW68DYtj8lWEI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1342935.RA8h_LShjGvH3a5uCYXStBIvuvBpVGIljW68DYtj8lWEI130_assertion type Assertion NP1342935.RA8h_LShjGvH3a5uCYXStBIvuvBpVGIljW68DYtj8lWEI130_head.
- NP1342935.RA8h_LShjGvH3a5uCYXStBIvuvBpVGIljW68DYtj8lWEI130_assertion description "[The transcriptional rate in these cells reached the maximum value after 40 h of treatment, and at that time it was three to four times higher than that of the control cells cultured in the absence of Asc 2-P. Steady-state levels of mRNAs for pro alpha 1(I) and pro alpha 2(I) chains were also increased to be three to four times higher than the control levels by treatment of the cells with Asc 2-P for 72 h. When the fibroblasts obtained from a patient with Ehlers-Danlos syndrome were treated with Asc 2-P, the derivative also stimulated transcription of the gene for pro alpha 1(I) chain and accumulation of mRNA for pro alpha 1(I) chain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1342935.RA8h_LShjGvH3a5uCYXStBIvuvBpVGIljW68DYtj8lWEI130_provenance.
- NP1342935.RA8h_LShjGvH3a5uCYXStBIvuvBpVGIljW68DYtj8lWEI130_assertion evidence source_evidence_literature NP1342935.RA8h_LShjGvH3a5uCYXStBIvuvBpVGIljW68DYtj8lWEI130_provenance.
- NP1342935.RA8h_LShjGvH3a5uCYXStBIvuvBpVGIljW68DYtj8lWEI130_assertion SIO_000772 8482361 NP1342935.RA8h_LShjGvH3a5uCYXStBIvuvBpVGIljW68DYtj8lWEI130_provenance.
- NP1342935.RA8h_LShjGvH3a5uCYXStBIvuvBpVGIljW68DYtj8lWEI130_assertion wasDerivedFrom befree-2016 NP1342935.RA8h_LShjGvH3a5uCYXStBIvuvBpVGIljW68DYtj8lWEI130_provenance.
- NP1342935.RA8h_LShjGvH3a5uCYXStBIvuvBpVGIljW68DYtj8lWEI130_assertion wasGeneratedBy ECO_0000203 NP1342935.RA8h_LShjGvH3a5uCYXStBIvuvBpVGIljW68DYtj8lWEI130_provenance.